key: cord-0015062-qp2z14xs
authors: Wang, Junmei
title: Fast Identification of Possible Drug Treatment of Coronavirus Disease −19 (COVID-19) Through Computational Drug Repurposing Study
date: 2020-02-21
journal: ChemRxiv
DOI: 10.26434/chemrxiv.11875446
sha: ae81240a8bde4f3f1716d13302d8b003afdbea90
doc_id: 15062
cord_uid: qp2z14xs

The recent outbreak of novel coronavirus disease −19 (COVID-19) calls for and welcomes possible treatment strategies using drugs on the market. It is very efficient to apply computer-aided drug design techniques to quickly identify promising drug repurposing candidates, especially after the detailed 3D-structures of key virous proteins are resolved. Taking the advantage of a recently released crystal structure of COVID-19 protease in complex with a covalently-bonded inhibitor, N3,(1) I conducted virtual docking screening of approved drugs and drug candidates in clinical trials. For the top docking hits, I then performed molecular dynamics simulations followed by binding free energy calculations using an endpoint method called MM-PBSA-WSAS.(2–4) Several promising known drugs stand out as potential inhibitors of COVID-19 protease, including Carfilzomib, Eravacycline, Valrubicin, Lopinavir and Elbasvir. Carfilzomib, an approved anti-cancer drug acting as a proteasome inhibitor, has the best MM-PBSA-WSAS binding free energy, −13.82 kcal/mol. Streptomycin, an antibiotic and a charged molecule, also demonstrates some inhibitory effect, even though the predicted binding free energy of the charged form (−3.82 kcal/mol) is not nearly as low as that of the neutral form (−7.92 kcal/mol). One bioactive, PubChem 23727975, has a binding free energy of −12.86 kcal/mol. Detailed receptor-ligand interactions were analyzed and hot spots for the receptor-ligand binding were identified. I found that one hotspot residue HIS41, is a conserved residue across many viruses including COVID-19, SARS, MERS, and HCV. The findings of this study can facilitate rational drug design targeting the COVID-19 protease.

A great application of drug repurposing is to identify drugs which were developed for treating other diseases to treat a new disease. Drug repurposing can be achieved by conducting systematic drug-drug target interaction (DTI) and drug-drug interaction (DDI) analyses. We have conducted a survey on DTIs collected by the DrugBank database 5 and found that on average each drug has 3 drug targets and each drug target has 4.7 drugs. 6 The analysis demonstrates that polypharmacology is a common phenomenon. It is important to identify potential DTIs for both approved drugs and drug candidates, which serves as the basis of repurposing drugs and selection of drug targets without DTIs that may cause side-effects. Polypharmacology opens novel avenues to rationally design next generation of more effective but less toxic therapeutic agents. Computer-aided drug design (CADD) has been playing essential roles in modern drug discovery and development. To balance the computational efficiency and accuracy, a hieratical strategy employing different types of scoring functions are applied in both the drug lead identification and optimization phases. A docking scoring function, such as the one employed by the Glide docking program, 7 is very efficient and thus can be utilized to screen a large library, but it is not very accurate. On the other hand, the molecular mechanical force field (MMFF)-based scoring functions, are physical and more accurate, but much less efficient. With the ever increasing computer power, MMFF-based free energy calculation methods, such as the endpoint MM-PB/GBSA (molecular mechanics-Poisson Boltzmann/ Generalized Born Surface Area) methods 2, 3, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] and the alchemical thermodynamic integration (TI) and free energy perturbation (FEP) methods, 22, 23 have been extensively applied in structure-based drug discovery projects. Recently we've developed a hierarchical virtual screening (HVS)to balance the efficiency and accuracy and improve the success rate of rational drug design. 8, 24 The newly released crystal structure of COVID-19 1 provides a solid structural basis for identification of drugs that might interact with this protein target. In this work, I applied multiscale modeling techniques to identify drugs that may be repurposed to target COVID-19 protease Flexible docking and MM-PBSA-WSAS were applied as the 1 st and 2 nd filters, respectively, to improve the efficiency and accuracy of HVS to identify inhibitors of COVID-19. Compared to the experimental means, CADD-based approaches are more efficient in providing possible treatment solutions for epidemic disease outbreaks like COVID-19.

The detailed ligand-residue interaction profile as well as the decomposition of binding free energy into different components provide insight into rationally designing potent and selective inhibitors targeting COVID-19 protease.

I conducted a hierarchical virtual screening (HVS) using the newly resolved crystal structure of COVID-19 protease (Resolution 2.16Å). 1 Two types of HVS filters were employed: Glide 7 flexible docking followed by MM-PBSA-WSAS. 2, 4 Detailed computational methods are described below.

The crystal structure was first treated using the protein structure preparation wizard provided by the Schrodinger software, followed by docking grid generation. Glide flexible docking was performed using the default settings except that the formation of intramolecular hydrogen bonds was rewarded and the enhancement of planarity of conjugated pi groups was turned on. The cocrystal ligand, N3, was covalently bonded to CYS145. I generated a new version of N3, N3' by breaking the covalent bond and filling in open valence. I then evaluated whether Glide flexible docking can reproduce the native binding pose. In addition, dataset of approved drugs was prepared using DrugBank, 5 and a set of PubChem compounds which are structurally similar to Lopinavir were enriched for docking screenings. Lopinavir, a potent inhibitor of HIV-1 protease, 25 was found effective in treating COVID-19 patients. Top hits from the docking screenings were advanced to the next HVS filter -MM-PBSA-WSAS.

MD simulations were first performed for a docking hit for two purposes: (1) studying the relative stability of the ligand residing in the binding pocket; (2) sampling a set of conformations for MM-PBSA-WSAS binding free energy calculations and MM-GBSA residue-ligand binding free energy decomposition analysis. A MD system consisted of one copy of COVID-19 protease, one copy of docked ligand, 17597 TIP3P 26 water molecules, about 50 Na + and Clions depending on the charge state of the ligand. The whole system was neutralized. For the force field parameters, the partial atomic charges of ligands were derived using the RESP 27 program to fit the HF/6-31G* electrostatic potentials generated using the GAUSSIAN 16 software package 28 . The other force field parameters were derived from GAFF 29 and the AMBER FF14SB 30 force field to model proteins. The residue topologies for ligands were prepared using the Antechamber module. 31 For the covalently-bonded N3 ligand, I applied the residuegen program to generate non-standard amino acid residue topology.

For a protein-ligand complex, the MD system was first relaxed through a series of minimization procedures. The mainchain atoms of the receptor and the bound ligand were restrained using a harmonic potential and its force constant decreased from 20 to 10, 5, 1 and 0 kcal/mol/Å 2 , progressively in five 10,000-step minimizations. Note that the last step applied no restraint at all as the force constant is 0. The system was further relaxed by a set of 100-picosecond atomistic MD simulations with the same restrain setting of minimizations.

There were three phases for a MD simulation: the relaxation phase, the equilibrium phase, and the sampling phase. In the relaxation phase, the simulation system was heated up progressively from 50 K to 250 K at steps of 50 K. At each temperature, a 1-nanosecond MD simulation was performed without any restraints or constraints. In the next equilibrium phase, the system was equilibrated at 298 K, 1 bar for 20 ns. Finally, a 100-nanosecond MD simulation was performed at 298 K, 1 bar to produce NTP (constant temperature and pressure) ensembles. In total, 10,000 snapshots were recorded from the last simulation. 200 snapshots were evenly selected for the MM-PBSA-WSAS binding free energy calculation and 5000 were selected for the MM-GBSA ligandprotein binding free energy decomposition analysis. Additional settings for constant pressure MD simulations performed in this work are listed as follows: temperature was regulated using Langevin dynamics 32 with a collision frequency of 5 ps -1 ; pressure was regulated using the isotropic position scaling algorithm with the pressure relaxation time set to 1.0 ps; integration of the equations of motion was conducted at a time step of 1 fs for the two relaxation phases and 2 fs for the equilibrium and sampling phases. The Particle Mesh Ewald (PME) method 33 was used to calculate the full electrostatic energy of a unit cell in a macroscopic lattice of repeating images. All bonds were constrained using the SHAKE algorithm 34 in both the minimization and MD simulation stages. All MD simulations were performed using the pmemd program in AMBER 18. 35

200 MD snapshots were evenly selected for the binding free energy calculations. For each selected MD snapshot, the molecular mechanical (MM) energy (EMM) and the MM-PBSA solvation free energy were calculated without further minimization. 8, 10, 11, [36] [37] [38] Key parameters controlling the MM-PBSA-WSAS analyses are listed as follows: external dielectric constant: 80; internal dielectric constant: 4; and the surface tension for estimating the nonpolar solvation energy by using solvent assessible surface area: 0.054. The Parse radii 39 were used in the MM-PBSA solvation calculation using the Delphi package (http://compbio.clemson.edu/delphi). The entropic term was estimated using a method coined WSAS (weighted solvent accessible surface area) described elsewhere. 4 It is noted that the entropic contribution cannot be neglected for this protein target as most ligands are large and have many rotatable bonds.

I conducted ligand-residue free energy decomposition analysis for 5000 snapshots evenly selected from the sampled snapshots. Besides the electrostatic and van der Waals interactions, the solvation effect was taken into account using a Generalized GB model developed by Onufriev et al. 40 The ligand-residue MM-GBSA interaction energies were calculated using the Sander program in AMBER18. 35 Data analysis was performed using an internal program developed by us. A hotspot residue is recognized when its ligand-residue MM-GBSA interaction is stronger than -1.0 kcal/mol.

In this work, I have performed two-step hierarchical virtual screenings to identify repurposing drugs targeting COVID-19 protease.

After downloading the crystal structure of COVID-19, I performed Glide docking screenings for a set of datasets (approved drugs, investigational drugs, and experimental drugs) downloaded from DrugBank. 5 I first evaluated the docking power of Glide for the co-crystal ligand of COVID-19, N3. The ligand RMSD of the best docking pose based on docking score (-9.398), 3.32 Å, was acceptable for a big ligand of about 100 atoms in flexible docking. I then applied the docking setting to conduct docking screenings. All the drug molecules that had docking scores better than -8.5 kcal/mol, which accounted for about 1% of total screening compounds, were selected as hits and advanced to the next filter -MM-PBSA-WSAS.

For the promising docking hits, I conducted molecular dynamics (MD) simulations using the AMBER software package. 35 In total 39 ligands including the co-crystal N3 ligand, were studied In summary, the RMSD fluctuation analysis suggests that the MD trajectories are overall stable during the sampling phase for all the studied MD systems.

I first generated the average structure of the collected snapshots, and then the MD snapshot that had the smallest main chain atom RMSD against the average structure was chosen as the representative conformation. The comparisons between the crystal structure and the representative MD conformations are shown in Figure 5 for the native ligand N3, and Figures 6-8 for the other ligands. As shown in Figure 5 , the benzene motif located in the dashed red cycle was inserted between two hotspot residues (HIS41 and MET49) for the MD structure, which is quite distinct from the crystal structure, which shows that the benzene motif has no direct interactions with HIS4 and MET49. I believe that under physiological conditions, the benzene motif becomes less solvent exposed and has more favorable interactions with HIS4 and MET49 by inserting itself between the side chains of the two residues. As shown below, both HIS4 and MET49 were hotspot residues in our MM-GBSA free energy decomposition analysis. Table S1 .

The values of each energy term, van der Waals (EVDW), electrostatics (EVDW + GPB), nonpolar solvation term (GSA), and entropy (TS), vary significantly from one system to another (Table 1 and Table S1 ), suggesting there is no single energy term that dominates the protein-ligand interaction.

For the charged drug molecules, caution should be taken in result interpretation. For example, the neural form of Streptomycin (DB01082) has a MM-PBSA-WSAS binding free energy of -7.92 kcal/mol, much better than the charged form (-3.82 kcal/mol). However, the latter is dominant under physiological conditions. We therefore should use the result of the charged form or take the penalty of protonation into consideration when using the result of the neutral form. 

I performed MM-GBSA binding free energy decomposition to identify the hotspot residues which make substantial contributions to the protein-ligand binding. The identified hotspots could enable us to rationally design potent and selective inhibitors of this drug target. To obtain statistically meaningful results, I studied 5000 MD snapshots for each system, and both the average ligand-residue interaction energies (Glig-res) and their RMSD values were calculated.

A hotspot residue is defined as a residue with Glig-res equal to or smaller than -1.0 kcal/mol.

The identified hotspots of each ligand are summarized in Table 2 . The most significant hotspot residues (Glig-res<-3.0) are illustrated in Figures 5-8 . The common significant hotspot residues for most ligands (in bold in Table 2) are as follows: HIS41, MET49, ASN142, HIS164, MET165, GLU166, and GLN189. Another consideration is the availability of high-quality drug target structures. Luckily, a highresolution crystal structure of COVID-19 protease in complex with a ligand was resolved timely, allowing us to conduct this drug repurpose screening. If no high-quality structure is available, one can rely on homology modeling technique, probably with a reduced success rate of identifying repurposing drugs. Take COVID-19 protease as an example, I performed structural alignments using an internal program which takes a multiple-sequence-alignment (MSA) as an input. The MSA was generated by using the Promals3D web server. 41 The structure of COVID-19 protease is found to be most similar to those of SARS protease (PDB Code 3TNT 42 ) and less similar to MERS protease (PDB Code 5WKK 43 ) ( Figure 9A ). In comparison, the structure of HCV NS3/4A

(PDB Code 3M5L 44 ) is quite different: the RMSD of 2.26 Å between HCV and COVID-19 is much larger and with only 108 residues participating the least-square fitting ( Figure 9B ). I also compared the sequences of the four proteases around the seven hotspot residues, which are colored in red in Table 3 . It is shown that COVID-19 and SARS share all the seven hotspot residues. MERS and COVID-19 have four of the seven common hotspot residues, while HCV NS3/4A and COVID-19 have only one common hotspot residue (H41). Even though the sequence identity is low between COVID-19 and HCV NS3/4A, as shown in Figure 9B , the co-crystal ligands, N3 (green sticks) for COVID-19 and ITMN-191 (brown sticks) for HCV NS3/4A, largely overlap. This suggests that homology models can be constructed using Modeller 45 with SARS, MERS and even HCV NS3/4A as templates. is 0.41 Å, but with 195 residues participating in the least-square fitting and 104 omitted. In contrast, the backbone RMSD between COVID-19 protease and HCV NS3/4A is 2.2632 Å, with 108 residues participating in the least-square fitting and 43 omitted.

In this study, I took advantage of the recently released crystal structure of COVID-19 protease and conducted multiscale drug repurposing screenings. Five neutral drugs, namely, Carfilzomib, Eravacycline, Valrubicin, Lopinavir and Elbasvir, are identified to have inhibitory activities against COVID-19 protease. Streptomycin, a charged molecule may also be an inhibitor of this COVID-19 protease. Our study suggests that computational drug repurposing screening is very efficient and it can provide potential repurposing drug candidates in less than five days. A set of hotspot residues which make substantial contributions to the protein-ligand binding are also identified, which can facilitate us to rationally design novel selective inhibitors targeting COVID-

ASSOCIATED CONTENT Supporting Information.

The MM-PBSA-WSAS binding free energies for other less promising docking hits (Glig-res worse than -5.0 kcal/mol) are listed in Table S1 .

Corresponding Author 

The crystal structure of COVID-19 main protease in complex with an inhibitor N3

End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design

Recent Advances in Free Energy Calculations with a Combination of Molecular Mechanics and Continuum Models

Develop and test a solvent accessible surface area-based model in conformational entropy calculations

Development and Testing of Druglike Screening Libraries

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy

Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA

Revisiting free energy calculations: a theoretical connection to MM/PBSA and direct calculation of the association free energy

Validation and use of the MM-PBSA approach for drug discovery

Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations

Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models

Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring

Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set

Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein-protein binding free energies and re-rank binding poses generated by protein-protein docking

Combined virtual screening, MMPBSA, molecular docking and dynamics studies against deadly anthrax: An in silico effort to inhibit Bacillus anthracis nucleoside hydrolase

Assessing the performance of MM/PBSA and MM/GBSA methods. 8. Predicting binding free energies and poses of protein-RNA complexes

Assessing the Performance of MM/PBSA, MM/GBSA, and QM-MM/GBSA Approaches on Protein/Carbohydrate Complexes: Effect of Implicit Solvent Models, QM Methods, and Entropic Contributions

Assessing the performance of MM/PBSA and MM/GBSA methods. 7. Entropy effects on the performance of endpoint binding free energy calculation approaches

Assessing the performance of the MM/PBSA and MM/GBSA methods. 10. Impacts of enhanced sampling and variable dielectric model on protein-protein Interactions

Assessing the performance of MM/PBSA and MM/GBSA methods. 9. Prediction reliability of binding affinities and binding poses for proteinpeptide complexes

Toward Fast and Accurate Binding Affinity Prediction with pmemdGTI: An Efficient Implementation of GPU-Accelerated Thermodynamic Integration

Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern freeenergy calculation protocol and force field

Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA

Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV

Comparison of simple potential functions for simulating liquid water

A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges-the RESP model

Development and testing of a general amber force field

Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB

Automatic atom type and bond type perception in molecular mechanical calculations

Langevin stabilization of molecular-dynamics simulations of polymers by means of quasisymplectic algorithms

New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations

Settle -an analytical version of the Shake and Rattle algorithm for rigid water models

Can MM-PBSA calculations predict the specificities of protein kinase inhibitors

An improved method to predict the entropy term with the MM/PBSA approach

Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking

Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models

Exploring protein native states and large-scale conformational changes with a modified generalized born model

PROMALS: towards accurate multiple sequence alignments of distantly related proteins

From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design

Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding

Comparative Protein Structure Modeling Using MODELLER